HTG Molecular Diagnostics and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene expression assays on HTG's fully automated, extraction-free Edge Platform.
The HTG Edge System is the only extraction-free, automated gene expression platform that delivers affordable, multiplexed results on lysed samples in less than a day.
The Edge System's multiplexing capability utilizing only one five-micron thick FFPE section provides a unique solution for the clinical laboratory professional.
OvaGene Oncology is entirely dedicated to helping women with gynecologic cancers by providing their treating oncologists with molecular tests developed using the latest advancements in gene-based diagnostics.
Each year in the USA there are approximately 84,000 women diagnosed with a gynecologic cancer: 22,000 cases of ovarian cancer; 52,000 cases of endometrial cancer; and, 12,000 cases of cervical cancer.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity